Abstract
Objective To determine how the severity of successively dominant SARS-CoV-2 variants has changed over the course of the COVID-19 pandemic.
Design Prospective cohort analysis.
Setting Community- and hospital- sequenced COVID-19 cases in the NHS Greater Glasgow and Clyde (NHS GG&C) Health Board (1.2 million people).
Participants All sequenced non-nosocomial adult COVID-19 cases in NHS GG&C identified to be infected with the relevant SARS-CoV-2 lineage during the following analysis periods. B.1.177/Alpha analysis: 1st November 2020 - 30th January 2021 (n = 1640). Alpha/Delta analysis: 1st April - 30th June 2021 (n = 5552). AY.4.2 Delta/non-AY.4.2 Delta analysis: 1st July – 31st October 2021 (n = 9613). Non-AY.4.2 Delta/Omicron analysis: 1st – 31st December 2021 (n = 3858).
Main outcome measures Admission to hospital, admission to ICU, or death within 28 days of first positive COVID-19 test
Results In the B.1.177/Alpha analysis, 300 of 807 (37.2%) B.1.177 cases were recorded as hospitalised or having a more severe outcome, compared to 232 of 833 (27.9%) Alpha cases. After adjusting for the following covariates: age, sex, time of positive test, comorbidities and partial postcode, the cumulative odds ratio was 1.51 (95% central credible interval 1.08-2.11) for Alpha versus B.1.177. In the Alpha/Delta analysis, 113 of 2104 (5.4%) Alpha cases were recorded as hospitalised or having a more severe outcome, compared to 230 of 3448 (6.7%) Delta cases. After adjusting for the above covariates plus number of vaccine doses and reinfection, the cumulative odds ratio was 2.09 (95% central credible interval 1.42-3.08) for Delta versus Alpha. In the non-AY.4.2 Delta/AY.4.2 Delta analysis, 845 of 8644 (9.8%) non-AY.4.2 Delta cases were recorded as hospitalised or having a more severe outcome, compared to 101 of 969 (10.4%) AY.4.2 Delta cases. After adjusting for the previously stated covariates, the cumulative odds ratio was 0.99 (95% central credible interval 0.76-1.27) for AY.4.2 Delta versus non-AY.4.2 Delta. In the non-AY.4.2 Delta/Omicron analysis, 30 of 1164 (2.6%) non-AY.4.2 Delta cases were recorded as hospitalised or having a more severe outcome, compared to 26 of 2694 (1.0%) Omicron cases. After adjusting for the previously listed covariates, the median cumulative odds ratio was 0.49 (95% central credible interval 0.22-1.06) for Omicron versus non-AY.4.2 Delta.
Conclusions The direction of change in disease severity between successively emerging SARS-CoV-2 variants of concern was inconsistent. This heterogeneity in virulence between variants, coupled with independent evolutionary emergence, demonstrates that severity associated with future SARS-CoV-2 variants is inherently unpredictable.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. Funding was also provided by UKRI through the JUNIPER consortium (grant number MR/V038613/1). Sequencing and bioinformatics support at the CVR was funded by the Medical Research Council (MRC) core award (MC UU 12014/12). We acknowledge the support of the G2P-UK National Virology Consortium (MR/W005611/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Anonymised clinical data were available using the NHS Greater Glasgow and Clyde (NHS GG&C) SafeHaven platform and included vaccination status (dates and product names for each dose), demographic data (age, sex and Scottish Index of Multiple Deprivation (SIMD) quartile) comorbidity (shielding and immunosuppression status) and dates of positive and negative PCR tests, for 1.2 million inhabitants of the (NHS GG&C) area over 18 years of age. Data were matched by CHI number and pseudonymised before analysis. Derogated ethical approval for the study was granted by the NHS GG&C SafeHaven committee (GSH/21/IM/001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
david.pascall{at}mrc-bsu.cam.ac.uk
Elen.Vink{at}glasgow.ac.uk
Guy.Mollett{at}ggc.scot.nhs.uk
Rachel.Blacow{at}ggc.scot.nhs.uk
naomi.bulteel2{at}nhs.scot
robyn.campbell{at}nhslothian.scot.nhs.uk
alasdair.campbell5{at}nhslothian.scot.nhs.uk
sarah.clifford{at}nhslothian.scot.nhs.uk
chris.davis{at}glasgow.ac.uk
ana.dasilvafilipe{at}glasgow.ac.uk
Ludmila.Fjodorova2{at}nhs.scot
ruth.forrest2{at}nhs.scot
Emily.Goldstein{at}ggc.scot.nhs.uk
Rory.Gunson{at}ggc.scot.nhs.uk
John.Haughney{at}ggc.scot.nhs.uk
matt.holden{at}nhs.scot
patrick.honour3{at}borders.scot.nhs.uk
joseph.hughes{at}glasgow.ac.uk
edward.james{at}borders.scot.nhs.uk
timothy.lewis{at}nhslothian.scot.nhs.uk
martin.mchugh{at}nhslothian.scot.nhs.uk
yusuke.onishi{at}nhs.scot
b.j.parcell{at}dundee.ac.uk
david.l.robertson{at}glasgow.ac.uk
noha.elsakka{at}nhs.scot
Sharif.Shaaban2{at}phs.scot
James.Shepherd.2{at}glasgow.ac.uk
katherine.smollett{at}glasgow.ac.uk
Kate.Templeton{at}nhslothian.scot.nhs.uk
elizabeth.wastnedge{at}nhslothian.scot.nhs.uk
thomaschristiewilliams{at}gmail.com
tommy.nyberg{at}mrc-bsu.cam.ac.uk
shaun.seaman{at}mrc-bsu.cam.ac.uk
Oscar.MacLean{at}glasgow.ac.uk
Craig.Wilkie{at}glasgow.ac.uk
surajit.ray{at}glasgow.ac.uk
Data Availability
Raw data is personally identifiable, and so are not available, but aggregated data are provided in the supplementary materials.
